Cortice Biosciences Announces Upcoming Clinical Trial Presentation at the 15th Annual Meeting of the American Association for Cancer Research
April 09, 2015 10:39 ET
|
Cortice Biosciences
NEW YORK, April 9, 2015 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that updated results from CB-017, a multi-center Phase 1/2 trial evaluating TPI 287 plus bevacizumab (Avastin®) for the...
Cortice Announces Enrollment of a Phase 1 Trial Evaluating TPI 287 Plus Radiotherapy for Treatment of Lung and Breast Cancer Metastases to the Brain
January 07, 2015 09:31 ET
|
Cortice Biosciences
NEW YORK, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that enrollment has begun in a Phase 1 clinical trial designed to determine safety and efficacy of TPI 287 in combination...
Cortice Biosciences Announces Initial Results From a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma
November 14, 2014 09:00 ET
|
Cortice Biosciences
– Objective responses in 7 out of 13 evaluable patients (5 confirmed and durable ≥ 5.5 months; 2 unconfirmed) treated with TPI 287 plus Avastin® –
– Disease control...
Cortice Biosciences Announces Results From Studies Evaluating Pipeline Candidates TPI 287 and CRT 001 in Preclinical Models of Tauopathies and Alzheimer's Disease
November 12, 2014 09:11 ET
|
Cortice Biosciences
— TPI 287 improves cognitive performance and reduces tau pathology —
— Activation of a critical neuronal cell signaling pathway and microglia activation by CRT 001 correlates...
Cortice Biosciences Announces Upcoming Presentations at the 2014 Cell Symposia for Translational Neuroscience and the Annual Meeting of the Society for Neuroscience
November 05, 2014 09:04 ET
|
Cortice Biosciences
NEW YORK, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that results from preclinical studies evaluating the activity of pipeline drug candidates CRT 001 and TPI 287 in models...
Cortice Biosciences Announces Upcoming Presentation at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
November 03, 2014 09:00 ET
|
Cortice Biosciences
NEW YORK, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that preliminary results from CB-017, a multi-center Phase 1/2 trial evaluating TPI 287 plus bevacizumab (Avastin®)...
Cortice Announces Acquisition of Exclusive Rights to a Novel Neurological Disease Therapeutic and Development Platform
July 31, 2014 09:49 ET
|
Cortice Biosciences
NEW YORK, July 31, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences, a company pioneering the development of oncologic and neurologic therapies for unmet medical needs, announced today that it has...
Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases
July 07, 2014 09:15 ET
|
Cortice Biosciences
NEW YORK, July 7, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that enrollment has begun in a Phase 1 trial designed to evaluate safety, tolerability and preliminary efficacy of the...
Cortice Announces Enrollment of a Phase 2 Trial Evaluating TPI 287 Plus Avastin(R) for Treatment of Glioblastoma Previously Treated with Anti-Angiogenic Therapy
March 20, 2014 09:00 ET
|
Cortice Biosciences
NEW YORK, March 20, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that enrollment has begun in the first stage of a Phase 2 open-label trial designed to evaluate the safety and efficacy...
Cortice Announces Enrollment of a Clinical Trial Targeting Tau Dysfunction in Mild-to-Moderate Alzheimer's Disease
January 21, 2014 10:00 ET
|
Cortice Biosciences
NEW YORK, Jan. 21, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that enrollment has begun in a Phase 1 open-label dose-escalation trial designed to evaluate safety, tolerability and...